BIOFILM INNOVATIONS GROUP, LLC – Trademark Portfolio
Entity Type: 16
BIOFILM INNOVATIONS GROUP, LLC holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include PAC5, EXXCL ORAL BLUE, and EXXCL SUDDENCOMFORT. The owner is based in BETHESDA, MD.
4905 EDGEMOOR LANE
BETHESDA, MD 208145307
Showing of trademarks Trademarks
Trademark Classifications
BIOFILM INNOVATIONS GROUP, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does BIOFILM INNOVATIONS GROUP, LLC have?
BIOFILM INNOVATIONS GROUP, LLC has 7 U.S. trademarks filed with the USPTO. Of these, 3 registered, 4 cancelled.
What trademark classes does BIOFILM INNOVATIONS GROUP, LLC file in?
BIOFILM INNOVATIONS GROUP, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are BIOFILM INNOVATIONS GROUP, LLC's most well-known trademarks?
BIOFILM INNOVATIONS GROUP, LLC's registered trademark portfolio includes well-known marks such as PAC5, EXXCL ORAL BLUE, and EXXCL SUDDENCOMFORT. These are among 3 currently registered trademarks in the portfolio.
What is BIOFILM INNOVATIONS GROUP, LLC's trademark registration success rate?
BIOFILM INNOVATIONS GROUP, LLC has a 43% trademark registration rate, with 3 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.